IPF treatment, NXP002, Continues to Show Promise in Preclinical Studies
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Vanda Pinto is a science writer for Pulmonary Fibrosis News with a PhD in biomedicine. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
30 April 2025| polaris.brighterir.com
The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The inv...| patents.google.com
NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.Tranilast has a long history of safe use as an oral drug for allergies but there is evidence (widely published in peer reviewed scientific papers) that supports its potential in fibrosis, including IPF.Overall findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated extra-c...| Nuformix
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News
